EMEA-001030-PIP01-10-M07

Key facts

Invented name
Invokana
Active substance
canagliflozin
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0205/2017
PIP number
EMEA-001030-PIP01-10-M07
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Janssen-Cilag International N.V.

E-mail: lpeeter8@its.jnj.com
Tel. +32 14 603 876

 

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating